Scientists studied a mutant that had a severe anemia because it had few blood stem cells, and also had a tail defect. The zebrafish mutants generally die within seven to ten days after fertilization. They discovered the mutation in the cdx4 gene, which is associated with the early blood deficiency as well as abnormal developmental patterning, including aberrant hox gene expression. When researchers injected the mutants with hox genes, such as hoxb7a and hoxa9a, it resulted in almost complete rescue of the deficient blood cells. Another hox gene, hoxb6b showed some improvement, but hoxb8a did not have any effect on the blood defect. Researchers believe this shows blood cell development is dependent on the proper expression of these hox genes, and that overexpression of these genes can reverse a fatal deficiency in these blood cells. "These zebrafish findings will allow us to better understand normal blood development, with the hopes of eventually developing more effective treatments for these devastating blood disorders such as leukemia," says Zon.
Children's Hospital Boston is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults for over 100 years. More than 500 scientists, including seven members of the National Academy of Sciences, nine members of the Institute of Medicine and nine members of the Howard Hughes Medical Institute comprise Children's research community. Founded in 1869 as a 20-bed hospital for children, Children's Hospital Boston today is a 300-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. It is also the primary pediatric teaching affiliate of Harvard Medical School. For more information about the hospital visit: www.childrenshospital.org.